Formulation and evaluation of orodispersible tablets of apremilast by inclusion complexation using β-cyclodextrin

Abstract

Introduction: The present study was carried out to formulate and evaluate orodispersible tablets of Apremilast with a purpose of providing better patient compliance to geriatric, pediatric, impaired, travelling and non-cooperative patients suffering from psoriasis. Such patients are in need of fast and easy swallowing drug delivery system. Materials and Methods: The Apremilast-β-cyclodextrin inclusion complex was prepared by physical blending method with a principle of increasing the solubility and permeability of drug. The inclusion efficiency of Apremilast: β-cyclodextrin ratios (1:1,1:2,1:3) were calculated and it was investigated that 1:2 ratio complex is highest. The orodispersible tablets of apremilast (F1 to F9) were prepared by simple and cost effective direct compression technique using different concentrations of super disintegrate croscarmellose sodium. Results: The results of pre-compression characteristics of powder blends and post-compression parameters of tablets were studied and showed satisfactory. Among all formulations studied, Formulation F6 showed less disintegration time and percent cumulative drug release 98.7% so it was declared as an optimized formulation. Conclusion: Therefore, It can be concluded that drug dissolution, absorption, therapeutic effect and bioavailability can be significantly greater than those as compared with conventional treatment of psoriasis in a cost-effective manner with better patient compliance.